June 24, 2008Hypertension
Tissue-Type Plasminogen Activator Release in Healthy Subjects and Hypertensive Patients
Why the study?
Does adrenergic stimulation modulate t-PA release differently in essential hypertensive patients compared to normotensive subjects?
Population
102 subjects, comprising 58 normotensive subjects and 44 essential hypertensive patients.
Comparison
Intrabrachial infusion of adrenergic stimuli… vs Normotensive subjects compared to essential…
Design
Cross-sectional
Authors
Discussion
Loading...
Member takes
Implication
May heighten thrombotic risk in hypertension; hypothesis-generating for NO-dependent fibrinolysis restoration.
Structured PICO
Does adrenergic stimulation modulate t-PA release differently in essential hypertensive patients compared to normotensive subjects?
P
Population
102 subjects, comprising 58 normotensive subjects (mean age 47+/-9 years) and 44 essential hypertensive patients (mean age 48+/-11 years).
I
Intervention
Intrabrachial infusion of adrenergic stimuli (epinephrine 0.1 to 0.3 microg/100 mL per minute, isoproterenol 0.03 microg/100 mL per minute) with or without NO synthase inhibition (N(G)-monomethyl-L-arginine 100 microg/100 mL per minute) or adrenergic blockers (phentolamine, propanolol).
C
Comparator
Normotensive subjects compared to essential hypertensive patients.
O
Outcome
Release of tissue-type plasminogen activator (t-PA) in the forearm microcirculation.surrogate
Adrenergic-stimulated t-PA release is impaired in essential hypertensive patients, likely due to reduced NO availability, which may contribute to increased cardiovascular risk.
Cite This Study
Giannarelli et al. (2008) studied this question.